Recruiting

Multisite rTMS for Mood, Cognitive Impairment and Other Symptoms of Depression

Depressed mood is the main symptom of depression, but other symptoms like cognitive impairment, anhedonia or sleep disorders may also contribute to patients suffering and are difficult to treat. rTMS is a relatively novel treatment option, whose therapeutic potential is still investigated and optimized. The aim of this study is to assess the effect of rTMS applied over two stimulation sites on cognitive impairment, anhedonia and sleep disorders in depression.

ClinicalTrials.gov IDNCT06363981

PhaseNA

Enrollment90

SponsorJakub Antczak

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Unipolar Depression, Bipolar Disorder

About this study

Interventions

Device: Active rTMS over the left DLPFC and over the left DMPFC — Active rTMS over the left DLPFC and over the left DMPFC to induce the long term potentiation of stimulated areas.
Device: Active rTMS over the left DLPFC — Active rTMS over the left DLPFC to induce the long term potentiation of stimulated area.
Device: Sham rTMS — Sham rTMS over the left DLPFC or over the left DLPFC and over the left DMPFC for placebo.

Primary outcomes

Beck Depression Inventory 2 (Before intervention - four weeks after finishing intervention.)
Froward digit span (Before intervention - four weeks after finishing intervention.)
Language part of Addenbrooke's Cognitive Examination (Before intervention - four weeks after finishing intervention.)

Eligibility information

Inclusion Criteria: * severe or moderate depressive episode (according to international classification of diseases (ICD)-10) without psychotic symptoms at the time of inclusion * Hamilton Depression Rating Scale between between 20 and 35 points at inclusion * The score in the Athens Insomnia Scale eight or more * The score of three or more points in items 4 and 21 of the Beck Depressions Inventory 2 * Complaining about problems with memory and concentration timely related with the onset of depression Exclusion Criteria: * Contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy * Psychotic symptoms at the time of inclusion * Suicidal ideations and/or attempts within three months prior to inclusion

Study locations

The Education of Research and Development Center, Babinski Clinical Hospital, Krakow, 30393 Poland

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-29.